AbbVie
ABBV
#28
Rank
NZ$643.16 B
Marketcap
NZ$363.91
Share price
0.41%
Change (1 day)
10.16%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

EPS for AbbVie (ABBV)

EPS in 2025 (TTM): NZ$2.32

According to AbbVie's latest financial reports the company's current EPS (TTM) is NZ$2.26. In 2024 the company made an earnings per share (EPS) of NZ$4.04 a decrease over its 2023 EPS that were of NZ$4.59.

EPS history for AbbVie from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$2.32-42.74%
2024NZ$4.04-11.86%
2023NZ$4.59-58.95%
2022NZ$11.182.49%
2021NZ$10.90121.58%
2020NZ$4.92-44.7%
2019NZ$8.9045.84%
2018NZ$6.109.72%
2017NZ$5.56-9.54%
2016NZ$6.1516.28%
2015NZ$5.29184.1%
2014NZ$1.86-57.15%
2013NZ$4.34

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.87 27.23%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$34.25 1,417.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$21.75 863.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$18.35 712.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$10.88 382.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$4.96 119.70%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$8.93 295.75%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$6.00 166.00%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$7.19 218.82%๐Ÿ‡บ๐Ÿ‡ธ USA